Follow VTRS's trial news. Pro members can get an alert when Viatris files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 1% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%.
Up 109% over the year to Nov 9 while the S&P 500 rose 12%; down 1% on Nov 5.
4 reasons, from its filings, with the timeline and its peers, for Pro members.
| Outperforming | Up 106% in a year vs the S&P's +12% |
| Latest filing | 8-K, Nov 5 |
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
VTRS closed −2.1% the next session (Oct 19).
Mon Nov 23: Ex-dividend, $0.12 a shareAt the open. Pays Dec 16.
After its last 4 reports it closed -1.3% on average, higher 1 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
CFO Paul Campbell sold 50,076 shares on Jun 25, under a planned sale. 1 more insider trade this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Excellentfor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means
VTRS is #6 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 6 |
Share count against a year before: VTRS -1.4%, TEVA +1.7%.
Expected to report Thu Feb 25, before the open (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $3.7B, about the same as a year ago; a loss of $0.28 a share, from $0.11.
“Generics net sales reflect contributions from new product launches and growth in certain products in North America, more than offset by continued supply constraints in Europe and Emerging Markets.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Brands | $2.5B | $2.4B | $2.4B |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| New product revenues | about $450M |
“The loss in the third quarter of 2026 was primarily driven by an increase in income tax provision due to losses in jurisdictions for which minimal benefit can be realized.”
From its results filing (SEC filing · Nov 5)
Sales grew 3.7% a year over 5 years, fiscal 2020 to 2025.
Pays $0.48 a share a year.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +1.1% | -1.3% | not yet |
| Aug 6, 2026 | +2.8% | -7.7% | -8.8% |
| May 7, 2026 | +5.2% | +9.0% | +8.9% |
Sales grew in three of the last seven years, to $14B in 2025. It made a profit in four of the eight years.
RSI 74.2, MACD above signal, above both averages. Not scored.
Its dividends come to 26% of its free cash flow.
| Dividend | $0.48 a share a year |
| Paid out | About $551M a year |
| Free cash flow | $2.1B |
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: VTRS is under 0.1% of VYM, under 0.1% of SPYI, and under 0.1% of VOO, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Jul 31, 2026.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
VTRS scores 16 today, which Breakaway calls Excellent. It is #6 of 90 in Pharma by Quality Score, with 8 of 14 chart checks firing. Down 1% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
VTRS scores 16 today, which Breakaway calls Excellent (15 to 19). That is #6 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VTRS's 16.
Expected to report Thu Feb 25, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. VTRS closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.